Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Extrapolated Biosimilar Indications Won't Get More US Post-Marketing Requirements

This article was originally published in PharmAsia News

Executive Summary

Biosimilars will have the same pharmacovigilance expectations as innovator biologics in the US despite the lack of clinical data for some extrapolated indications.


Related Content

Biosimilar Interchangeability Requirements Pushed At Inflectra Review


Related Companies